Individually Tailored Physiotherapy in Persons With Respiratory Symptoms Related to Post-Acute Sequelae of COVID-19: A Feasibility Study With Mixed Methods

针对新冠肺炎后急性期呼吸系统症状患者的个体化物理治疗:一项采用混合方法的可行性研究

阅读:1

Abstract

BACKGROUND AND AIMS: Post-acute sequelae of COVID-19 (PASC) commonly present with persistent respiratory symptoms, even in individuals with normal chest imaging and pulmonary function. Given the heterogeneity within this population, a personalized approach to respiratory physiotherapy could improve outcomes. The purpose of this study was to assess the feasibility and impact of a tailored respiratory physiotherapy program on health-related quality of life (QoL), functional impairment, and patient-reported outcome measures (PROMs) in individuals with persistent respiratory symptoms due to PASC. METHODS: A single-arm, open-label trial was conducted with 13 adults diagnosed with PASC, recruited from Long COVID clinics in Calgary, Canada. Participants underwent an 8-session personalized physiotherapy program, including education, breathing exercises, and strengthening. Feasibility was measured through recruitment, retention, and session completion rates. PROMs were collected at baseline and post-intervention, and qualitative interviews explored participant perspectives. RESULTS: The program was highly feasible, with 100% retention and a 99% completion rate. Significant improvements were observed in QoL, functional status (Post COVID-19 Function Status scale), and self-efficacy scores. The 6-min walk test showed clinically meaningful improvements in three out of seven participants. Qualitative interviews (n = 8) identified three main themes: struggles with PASC, positive aspects of the program, and benefits from completing it. Participants valued the personalized approach, heart rate monitors, flexible scheduling, and a hybrid of in-person and virtual sessions, reporting increased confidence, improved symptom management, and better mental health. CONCLUSION: A personalized respiratory physiotherapy program is feasible and may benefit individuals with PASC. Larger trials are needed to assess long-term efficacy and scalability. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05040893.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。